112 related articles for article (PubMed ID: 8678035)
1. p53 mutation in hepatocellular carcinoma and chronic liver disease.
Ceyhan K; Akpolat I; Bozdoğan N; Kobat I; Ekinci C
Am J Gastroenterol; 1996 Jul; 91(7):1476-7. PubMed ID: 8678035
[No Abstract] [Full Text] [Related]
2. [Global epidemiology of hepatocellular carcinoma].
Kiyosawa K; Sodeyama T
Nihon Rinsho; 2001 Oct; 59 Suppl 6():13-9. PubMed ID: 11761928
[No Abstract] [Full Text] [Related]
3. [p53 and hepatocellular carcinomas].
Mihm S; Leonhardt U; Ramadori G
Z Gastroenterol; 1993 Sep; 31(9):498-9. PubMed ID: 8237091
[No Abstract] [Full Text] [Related]
4. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers.
Yu MW; Yang SY; Chiu YH; Chiang YC; Liaw YF; Chen CJ
Hepatology; 1999 Mar; 29(3):697-702. PubMed ID: 10051470
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
6. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
7. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
8. [p53 gene mutation in hepatocellular carcinoma].
Jiang W; Lu Q; Pan G
Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):531-2. PubMed ID: 11825456
[TBL] [Abstract][Full Text] [Related]
9. The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study.
Matsuzaki Y; Sato M; Saito Y; Karube M; Doy M; Shoda J; Abei M; Tanaka N; Hadama T; Kinoshita M
J Exp Clin Cancer Res; 1999 Sep; 18(3):379-89. PubMed ID: 10606185
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.
Cengiz C; Akarca US; Goker E; Yuce G
Dig Dis Sci; 2003 May; 48(5):865-9. PubMed ID: 12772781
[TBL] [Abstract][Full Text] [Related]
11. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
Hosny G; Farahat N; Tayel H; Hainaut P
Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
[TBL] [Abstract][Full Text] [Related]
12. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
[TBL] [Abstract][Full Text] [Related]
13. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
15. [Tumor suppressor gene, p53, and hepatocarcinogenesis].
Masutomi K; Kaneko S; Kobayashi K
Nihon Rinsho; 2001 Oct; 59 Suppl 6():138-41. PubMed ID: 11761930
[No Abstract] [Full Text] [Related]
16. [Clinical and molecular correlation between chronic hepatitis and hepatocellular carcinoma induced by hepatitis B virus].
Shapiro IIa; Shabrov AV; Karev VE; Leenman EE; Kvetnoĭ IM; Tsinzerling VA; Sologub TV
Arkh Patol; 2005; 67(2):6-10. PubMed ID: 15938110
[TBL] [Abstract][Full Text] [Related]
17. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
18. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
Szymañska K; Chen JG; Cui Y; Gong YY; Turner PC; Villar S; Wild CP; Parkin DM; Hainaut P
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1638-43. PubMed ID: 19366907
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation.
Caruso ML; Valentini AM
Anticancer Res; 1999; 19(5B):3853-6. PubMed ID: 10628323
[TBL] [Abstract][Full Text] [Related]
20. TP53 and liver carcinogenesis.
Staib F; Hussain SP; Hofseth LJ; Wang XW; Harris CC
Hum Mutat; 2003 Mar; 21(3):201-16. PubMed ID: 12619106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
